Endovenous embolization of pelvic congestion syndrome: Impact on pain, sexual function, and quality of life—A multidisciplinary prospective single-arm cohort study Authors: Tolga Onur Badak, Ferid Cereb, Ahmet Cakallioglu, Selim Polat, Hacı Ali Ucak, Hasan Uncu Published: 2026 ABSTRACT ObjectiveThis prospective cohort study evaluated the impact of endovenous ovarian vein embolization (OVE) on pain, sexual function, psychiatric symptoms, and quality of life in patients with pelvic congestion syndrome (PCS).MethodsEighty women with PCS aged 18 to 55 years presenting with chronic pelvic pain (visual analog scale [VAS] ≥4) lasting ≥6 months underwent OVE. Patients with confirmed pelvic venous reflux on venous reflux Doppler ultrasound examination using 3- to 5-MHz probes in supine and standing positions were classified using the 2021 Symptoms-Varices-Pathophysiology system. Outcomes were assessed at baseline, 3, and 6 months using a VAS, the Female Sexual Function Index (FSFI), the Arizona Sexual Experiences Scale (ASEX), the Hamilton Depression and Anxiety scales, and the Short Form-36 quality-of-life instrument. Statistical analysis included paired t-tests, Cohen's d effect sizes, and multivariate logistic regression. An a priori power analysis (G∗Power 3.1; Cohen's d = 0.8; power = 0.95) required a minimum of 68 participants. Patient recruitment occurred between February 2025 and August 2025, with 6-month follow-up assessments completed by February 2026.ResultsThe mean patient age was 36.7 ± 4.6 years with a parity of 3.6 ± 1.4. Most patients (67.5%) were S2-V2-PBGV,R,NT classification. At 6 months, significant improvements occurred: the VAS decreased 3.12 ± 2.51 points (Cohen's d = 1.68; P < .001), the FSFI score increased 7.28 ± 4.86 points (d = 1.21; P < .001), the ASEX score decreased 9.45 ± 6.34 points (d = 1.47; P < .001), the Hamilton Depression scale decreased 6.8 ± 3.6 points (P < .001), the Hamilton Anxiety scale decreased 8.1 ± 4.2 points (P < .001), and quality of life increased 28.42 ± 16.15 points (d = 2.24; P < .001). Response rates were 88.7% (VAS/quality of life), 86.2% (FSFI), and 87.5% (ASEX). Pelvic pain decreased in 93.7%, dyspareunia improved in 91.2%, and vaginismus resolved in 95.2%. Minor complications occurred in 6.25%. Dysmenorrhea (odds ratio [OR], 3.24), high parity (≥4 births; OR, 2.87), and prolonged symptom duration (≥2 years; OR, 2.15) were independent predictors of response.ConclusionsEndovenous OVE provides sustained, multidimensional improvement in patients with PCS, significantly enhancing sexual function, psychiatric health, and quality of life. Although the single-arm design limits causal attribution, the high response rates and favorable safety profile substantiate significant clinical benefit. The multidisciplinary management approach validates the importance of integrating vascular surgery and psychiatry. Article Highlights •Type of Research: Prospective single-arm cohort study•Key Findings: Endovenous ovarian vein embolization produces significant improvements in pain, sexual function, and quality of life in pelvic congestion syndrome.•Take Home Message: Embolization addresses core venous pathophysiology with broad-spectrum benefits, validating multidisciplinary management. Six-month response rates were high: 88.7% for pain (visual analog scale), 86.2% for sexual function (Female Sexual Function Index), and 88.7% for quality of life. Dyspareunia improved in 91.2% of patients and vaginismus resolved in 95.2%. Significant decreases in depression (65% remission) and anxiety (77.5% remission) were achieved. The procedure demonstrated a favorable safety profile, with a 6.25% minor complication rate. Article Highlights •Type of Research: Prospective single-arm cohort study•Key Findings: Endovenous ovarian vein embolization produces significant improvements in pain, sexual function, and quality of life in pelvic congestion syndrome.•Take Home Message: Embolization addresses core venous pathophysiology with broad-spectrum benefits, validating multidisciplinary management. Six-month response rates were high: 88.7% for pain (visual analog scale), 86.2% for sexual function (Female Sexual Function Index), and 88.7% for quality of life. Dyspareunia improved in 91.2% of patients and vaginismus resolved in 95.2%. Significant decreases in depression (65% remission) and anxiety (77.5% remission) were achieved. The procedure demonstrated a favorable safety profile, with a 6.25% minor complication rate. •Type of Research: Prospective single-arm cohort study Type of Research: Prospective single-arm cohort study •Key Findings: Endovenous ovarian vein embolization produces significant improvements in pain, sexual function, and quality of life in pelvic congestion syndrome. Key Findings: Endovenous ovarian vein embolization produces significant improvements in pain, sexual function, and quality of life in pelvic congestion syndrome. •Take Home Message: Embolization addresses core venous pathophysiology with broad-spectrum benefits, validating multidisciplinary management. Six-month response rates were high: 88.7% for pain (visual analog scale), 86.2% for sexual function (Female Sexual Function Index), and 88.7% for quality of life. Dyspareunia improved in 91.2% of patients and vaginismus resolved in 95.2%. Significant decreases in depression (65% remission) and anxiety (77.5% remission) were achieved. The procedure demonstrated a favorable safety profile, with a 6.25% minor complication rate. Take Home Message: Embolization addresses core venous pathophysiology with broad-spectrum benefits, validating multidisciplinary management. Six-month response rates were high: 88.7% for pain (visual analog scale), 86.2% for sexual function (Female Sexual Function Index), and 88.7% for quality of life. Dyspareunia improved in 91.2% of patients and vaginismus resolved in 95.2%. Significant decreases in depression (65% remission) and anxiety (77.5% remission) were achieved. The procedure demonstrated a favorable safety profile, with a 6.25% minor complication rate. Venous insufficiency in the pelvic region is a common but frequently underdiagnosed pathology affecting women of reproductive age. Pelvic congestion syndrome (PCS) is present in approximately 10% of the general female population, with 5% to 10% of women presenting with chronic pelvic pain receiving a PCS diagnosis. The Symptoms-Varices-Pathophysiology (SVP) classification published by the American Vein & Lymphatic Society in 2021 standardized symptom severity, anatomical distribution of varices, and pathophysiological mechanisms, significantly increasing comparability between studies.1 This classification system has revolutionized the approach to PCS diagnosis and management by providing a standardized framework that accounts for the heterogeneity of clinical presentations and enables more accurate patient stratification. Endovenous embolization has become the first-line treatment with technical success rates of 95% to 100%.2 Clinical presentation in PCS is highly variable, with patients presenting with chronic pelvic pain, dyspareunia, dysmenorrhea, and urogenital symptoms that significantly impact quality of life. Dyspareunia is one of the most distressing symptoms, capable of leading to anticipation anxiety, performance anxiety, sexual avoidance behaviors, and depressive symptoms over time. Studies report depression prevalence of 25% to 50% and anxiety prevalence of 10% to 20% in patients with PCS.3,4 The psychosocial burden of PCS extends beyond physical symptoms, affecting intimate relationships, social functioning, and overall psychological well-being. The impact on sexual function is particularly significant; dyspareunia can lead to relationship dysfunction and social isolation. Although PCS is closely associated with psychiatric comorbidities, multidisciplinary studies systematically examining the effect of endovenous treatments on psychosexual parameters are limited. Most existing studies evaluate treatment success solely based on pain scores; patient-centered outcomes such as sexual function, psychological state, and quality of life remain underexplored. The integration of psychiatric assessment into vascular disease management represents a paradigm shift in understanding and treating chronic venous disease. This study aimed to comprehensively evaluate endovenous ovarian vein embolization (OVE) impact on pain, sexual function, psychiatric symptoms, and quality of life from a multidisciplinary cardiovascular surgery and psychiatry perspective, using the 2021 SVP classification. Fig 1 illustrates the SVP classification distribution across symptom level, varicose vein distribution, and pathophysiological subgroups in the study cohort.Fig 1Symptoms-Varices-Pathophysiology (SVP) classification distribution. Symptoms-Varices-Pathophysiology (SVP) classification distribution. Methods Study design and patient population This prospective single-arm cohort study included 80 women with PCS aged 18 to 55 years presenting with chronic pelvic pain (visual analog scale [VAS] ≥4) lasting ≥6 months. Inclusion criteria were pelvic venous reflux confirmed by venous reflux Doppler ultrasound (VRDUS) examination with a ≥5-mm diameter ovarian/uterine veins and retrograde flow, PCS diagnosis confirmed by venography, complete 6-month follow-up, and written informed consent. Exclusion criteria were age <18 or >55 years, secondary pathologies, coagulation disorders, active anticoagulation (except aspirin), prior pelvic surgery (except cesarean section), regular opioid use, pregnancy/lactation, severe psychiatric illness, or contrast allergy.5 Patient recruitment occurred between February 2025 and August 2025, with final 6-month follow-up assessments completed by February 2026. Follow-up assessments at 1, 3, and 6 months included clinical examination and VRDUS to confirm persistent occlusion and assess for recurrent reflux. The study protocol was approved by the institutional review board (protocol 2025-10/347) and conducted in accordance with the Declaration of Helsinki. All participants provided written informed consent after receiving detailed information about the study procedures and potential risks and benefits. The study was designed to address the gap in the multidisciplinary assessment of PCS treatment outcomes. Diagnostic methods and technical specifications VRDUS was performed using 3- to 5-MHz linear transducers with the patient in supine and standing positions. Anatomical windows included the pelvic inlet, midpelvis, and pelvic floor. Venous reflux was assessed during Valsalva maneuver with a >0.5-second duration considered significant.6 Definitive diagnosis was made by venography under local anesthesia using the right jugular vein approach. Patients were classified according to the 2021 SVP classification.1 The SVP system evaluates three key components: symptom severity (S0-S3 scale), distribution of varices (V0-V3 scale), and pathophysiological mechanisms (primary, secondary, or combined). This classification system allows for better characterization of disease phenotype and prediction of treatment outcomes. Patient demographics and baseline characteristics are presented in Table I. Table II shows the SVP classification distribution and anatomical subtypes among the study population, demonstrating the heterogeneity of disease presentation. Table III displays baseline clinical findings and imaging parameters for all enrolled patients, including venous diameter measurements and reflux duration.Table IDemographic and clinical characteristics of the study population (N = 80)ParameterNo. (%) or mean ± SDRange95% CIDemographic characteristics Age, years36.7 ± 4.628-5735.7-37.7 BMI (kg/m2)26.8 ± 3.419.2-34.126.0-27.5Occupation Housewife62 (77.5)–– Self-employed8 (10.0)–– Civil servant5 (6.25)–– Private sector3 (3.75)–– Commerce2 (2.5)––Education status–– Primary school33 (41.25)–– High school30 (37.5)–– University15 (18.75)–– Postgraduate2 (2.5)––Obstetric history Marriage duration, years15.8 ± 5.27-4014.6-16.9 Gravida4.2 ± 1.61-93.8-4.5 Parity3.6 ± 1.41-83.3-3.9 Normal delivery2.8 ± 1.30-72.5-3.1 Cesarean section0.8 ± 0.90-30.6-1.0 Living children3.5 ± 1.31-83.2-3.8 Time since last delivery, years8.4 ± 4.72-227.4-9.4Risk factors Family history of varicose veins37 (46.25)–– Smoking12 (15.0)–– Prolonged standing (>4 hours/day)28 (35.0)––Symptom characteristics Pelvic pain duration, months32.5 ± 18.66-9628.4-36.6 Pelvic pain duration ≥24 months47 (58.75)–– Presence of dysmenorrhea53 (66.25)–– Dysmenorrhea severity (VAS)5.8 ± 2.10-95.3-6.3 Presence of dyspareunia76 (95.0)–– Dyspareunia severity (VAS)6.2 ± 1.80-105.8-6.6 Postcoital pain68 (85.0)–– Vulvar/perineal varices54 (67.5)–– Lower extremity varices71 (88.75)––Previous treatments–– Hormonal therapy trial42 (52.5)–– Regular analgesic use61 (76.25)–– Physical therapy trial18 (22.5)––BMI, Body mass index; SD, standard deviation; VAS, visual analog scale.Table IIDistribution of patients according to the Symptoms-Varices-Pathophysiology (SVP) classificationSVP CategoryNo. (%)DescriptionSymptom level (S) S18 (10.0)Mild symptoms S254 (67.5)Moderate symptoms S318 (22.5)Severe symptomsVaricose vein distribution (V) V16 (7.5)Only vulvar/perineal V220 (25.0)Only lower extremity V354 (67.5)Both vulvar and lower extremityPathophysiology (P) PB,R,NT9 (11.25)Isolated pelvic vein reflux PBGV,R,NT17 (21.25)Pelvic + genital veins PBGVL,R,NT54 (67.5)Pelvic + genital + lower extremityCombined classification S2-V3-PBGVL,R,NT38 (47.5)Most frequent S3-V3-PBGVL,R,NT16 (20.0)Most severe S2-V2-PBGV,R,NT12 (15.0)Moderate severity Other combinations14 (17.5)VariousTable IIIVenographic findings and anatomical variations observed in the study cohortFindingValueOvarian vein diameter (basal) Left ovarian vein mean, mm8.4 ± 2.1 (range, 5.2-14.3) Right ovarian vein mean, mm7.6 ± 1.9 (range, 5.0-12.8)Reflux pattern Bilateral ovarian vein reflux68 (85.0) Only left ovarian vein reflux10 (12.5) Only right ovarian vein reflux2 (2.5)Internal iliac vein involvement Bilateral internal iliac tributary reflux47 (58.75) Unilateral internal iliac reflux22 (27.5) No internal iliac involvement11 (13.75)Anatomical variations Left ovarian vein → renal vein (normal)72 (90.0) Left ovarian vein → common iliac vein6 (7.5) Left ovarian vein → IVC direct2 (2.5) Right ovarian vein double lumen8 (10.0)Associated findings May-Thurner syndrome12 (15.0) Nutcracker phenomenon (left renal vein compression)8 (10.0) Azygos system connection15 (18.75) Uterine arcade prominent dilatation62 (77.5)IVC, Inferior vena cava.Values are mean ± standard deviation or number (%). Table IDemographic and clinical characteristics of the study population (N = 80)ParameterNo. (%) or mean ± SDRange95% CIDemographic characteristics Age, years36.7 ± 4.628-5735.7-37.7 BMI (kg/m2)26.8 ± 3.419.2-34.126.0-27.5Occupation Housewife62 (77.5)–– Self-employed8 (10.0)–– Civil servant5 (6.25)–– Private sector3 (3.75)–– Commerce2 (2.5)––Education status–– Primary school33 (41.25)–– High school30 (37.5)–– University15 (18.75)–– Postgraduate2 (2.5)––Obstetric history Marriage duration, years15.8 ± 5.27-4014.6-16.9 Gravida4.2 ± 1.61-93.8-4.5 Parity3.6 ± 1.41-83.3-3.9 Normal delivery2.8 ± 1.30-72.5-3.1 Cesarean section0.8 ± 0.90-30.6-1.0 Living children3.5 ± 1.31-83.2-3.8 Time since last delivery, years8.4 ± 4.72-227.4-9.4Risk factors Family history of varicose veins37 (46.25)–– Smoking12 (15.0)–– Prolonged standing (>4 hours/day)28 (35.0)––Symptom characteristics Pelvic pain duration, months32.5 ± 18.66-9628.4-36.6 Pelvic pain duration ≥24 months47 (58.75)–– Presence of dysmenorrhea53 (66.25)–– Dysmenorrhea severity (VAS)5.8 ± 2.10-95.3-6.3 Presence of dyspareunia76 (95.0)–– Dyspareunia severity (VAS)6.2 ± 1.80-105.8-6.6 Postcoital pain68 (85.0)–– Vulvar/perineal varices54 (67.5)–– Lower extremity varices71 (88.75)––Previous treatments–– Hormonal therapy trial42 (52.5)–– Regular analgesic use61 (76.25)–– Physical therapy trial18 (22.5)––BMI, Body mass index; SD, standard deviation; VAS, visual analog scale. Demographic and clinical characteristics of the study population (N = 80) BMI, Body mass index; SD, standard deviation; VAS, visual analog scale. Table IIDistribution of patients according to the Symptoms-Varices-Pathophysiology (SVP) classificationSVP CategoryNo. (%)DescriptionSymptom level (S) S18 (10.0)Mild symptoms S254 (67.5)Moderate symptoms S318 (22.5)Severe symptomsVaricose vein distribution (V) V16 (7.5)Only vulvar/perineal V220 (25.0)Only lower extremity V354 (67.5)Both vulvar and lower extremityPathophysiology (P) PB,R,NT9 (11.25)Isolated pelvic vein reflux PBGV,R,NT17 (21.25)Pelvic + genital veins PBGVL,R,NT54 (67.5)Pelvic + genital + lower extremityCombined classification S2-V3-PBGVL,R,NT38 (47.5)Most frequent S3-V3-PBGVL,R,NT16 (20.0)Most severe S2-V2-PBGV,R,NT12 (15.0)Moderate severity Other combinations14 (17.5)Various Distribution of patients according to the Symptoms-Varices-Pathophysiology (SVP) classification Table IIIVenographic findings and anatomical variations observed in the study cohortFindingValueOvarian vein diameter (basal) Left ovarian vein mean, mm8.4 ± 2.1 (range, 5.2-14.3) Right ovarian vein mean, mm7.6 ± 1.9 (range, 5.0-12.8)Reflux pattern Bilateral ovarian vein reflux68 (85.0) Only left ovarian vein reflux10 (12.5) Only right ovarian vein reflux2 (2.5)Internal iliac vein involvement Bilateral internal iliac tributary reflux47 (58.75) Unilateral internal iliac reflux22 (27.5) No internal iliac involvement11 (13.75)Anatomical variations Left ovarian vein → renal vein (normal)72 (90.0) Left ovarian vein → common iliac vein6 (7.5) Left ovarian vein → IVC direct2 (2.5) Right ovarian vein double lumen8 (10.0)Associated findings May-Thurner syndrome12 (15.0) Nutcracker phenomenon (left renal vein compression)8 (10.0) Azygos system connection15 (18.75) Uterine arcade prominent dilatation62 (77.5)IVC, Inferior vena cava.Values are mean ± standard deviation or number (%). Venographic findings and anatomical variations observed in the study cohort IVC, Inferior vena cava. Values are mean ± standard deviation or number (%). Treatment protocol Endovenous OVE was performed during the same session as diagnostic venography when PCS was confirmed. A standardized endovenous embolization protocol was applied in all patients. After ≥6 hours of fasting, prophylactic cefazolin 1 g was administered intravenously, and the procedure was performed under local anesthesia with 2% lidocaine. The right internal jugular vein was punctured under ultrasound guidance, a 5F sheath was introduced, and an 0.035-inch hydrophilic guidewire was advanced to the inferior vena cava. Selective ovarian vein catheterization was performed using a 5F multipurpose catheter, followed by venography to confirm reflux and map anatomical variations. Embolization was performed from the distal refluxing segment proximally to 1 to 2 cm below the renal vein confluence using fibered platinum coils and, when appropriate, vascular plug materials and/or sclerosing agents. Technical success was defined as complete occlusion of the treated ovarian vein and tributaries with no residual reflux on completion venography. After sheath removal, manual compression was applied, patients were observed with 4 hours of bed rest, oral hydration and analgesia were provided as required, and same-day discharge was planned in uncomplicated cases; 7 days of light activity restriction and oral anti-inflammatory therapy were prescribed. Psychiatric integration was maintained throughout the study. All patients received psychological support during sensitive survey administration, with a trained psychologist present during assessment sessions. Psychiatric collaboration occurred during initial patient assessment and continued throughout treatment and follow-up, allowing structured evaluation of psychiatric symptoms and sexual function. This multidisciplinary approach addressed the psychosocial burden of PCS and recognized chronic pelvic pain as a condition with both vascular and psychological components.7 Predetermined responder thresholds were based on established minimally clinically important differences from the literature: a ≥3-point increase in the FSFI (based on published minimally clinically important differences for sexual function assessment), a ≥5-point decrease in the ASEX (representing clinically meaningful improvement in sexual experiences), and a ≥2-point decrease on the VAS (standard threshold for pain reduction in chronic pain studies).8 These thresholds are consistent with international guidelines for clinical trial outcome assessment and have been validated in similar patient populations. Cohort-specific data were used to confirm the statistical significance of changes in scores, ensuring thresholds were appropriate for our study population. Statistical analyses Statistical analyses were performed using SPSS 27.0 (IBM) and R 4.2.1 (The R Foundation for Statistical Computing). Paired t-tests compared pretreatment and post-treatment measurements. Cohen's d effect sizes were calculated to quantify the magnitude of treatment effects. An a priori power analysis (G∗Power 3.1, Cohen's d = 0.8; alpha = 0.05; power = 0.95) for paired t-tests required a minimum of 68 participants. Multivariate logistic regression identified predictors of treatment response, with odds ratios (ORs) and 95% confidence intervals (CIs) calculated. Repeated measures analysis of variance was used to assess changes across the three time points (baseline, 3 months, and 6 months). Missing data were handled using an intention-to-treat analysis with a last-observation-carried-forward imputation for participants who did not complete follow-up.9 Results Eighty patients were enrolled with a mean age of 36.7 ± 4.6 years and parity of 3.6 ± 1.4. Most patients (67.5%) were classified as S2-V2-PBGV,R,NT per the SVP classification. No patients were lost to follow-up during the 6-month study period. Anatomical and venographic findings Venographic assessment demonstrated frequent bilateral venous involvement and relevant anatomical variations. The mean left ovarian vein diameter was 8.4 mm, and the mean right ovarian vein diameter was 7.6 mm. Bilateral ovarian vein reflux was present in 85% of patients. Internal iliac vein reflux was also common, occurring bilaterally in 58.75% and unilaterally in 27.50% of patients. The left ovarian vein drained into the left renal vein in 90.0% of patients, whereas drainage to the common iliac vein and inferior vena cava was observed in 7.5% and 2.5%, respectively. A right ovarian vein double-lumen variation was identified in 10% of patients. Associated venous findings included May-Thurner syndrome in 15.00%, nutcracker phenomenon in 10.00%, azygos system connection in 18.75%, and prominent uterine arcade dilatation in 77.50%. These findings support the heterogeneous venous anatomy of PCS and the need for individualized venographic mapping before embolization. Treatment characteristics and technical success The embolization procedure was technically successful in all patients (100%). The mean total procedure time was 42.3 minutes, and the mean fluoroscopy time was 18.5 minutes. Coil-only embolization was used in 60% of patients, coil plus Amplatzer vascular plug in 35%, and coil plus sclerotherapy in 5%. The mean number of coils was 4.8 for the left ovarian vein and 4.2 for the right ovarian vein. Bilateral OVE was performed in 85% of patients, and internal iliac vein tributary embolization was added in approximately 59% based on venographic reflux patterns. Completion venography confirmed complete occlusion and absence of residual reflux in all treated venous segments. Table IV presents the outcome measures at baseline, 3 months, and 6 months with P values and effect sizes for all primary outcome measures. The table demonstrates consistent improvement across all measured domains.Table IVTechnical details and success rates of endovenous ovarian vein embolization (OVE) proceduresParameterMean ± SD or no. (%)RangeProcedure durations Total procedure time, minutes42.3 ± 12.825-78 Fluoroscopy time, minutes18.5 ± 6.210-35Embolization materials Coil-only use48 (60.0)- Coil + plug combination28 (35.0)- Coil + sclerotherapy4 (5.0)- Mean coil number (left ovarian vein)4.8 ± 1.62-9 Mean coil number (right ovarian vein)4.2 ± 1.52-8 Plug use (Amplatzer)28 (35.0)-Embolized veins Bilateral ovarian vein68 (85.0)- Only left ovarian vein10 (12.5)- Only right ovarian vein2 (2.5)- Internal iliac vein tributaries (additional)47 (58.75)-Technical success Complete embolization success80 (100)- Complete occlusion on control venography80 (100)- No residual reflux80 (100)- Table IVTechnical details and success rates of endovenous ovarian vein embolization (OVE) proceduresParameterMean ± SD or no. (%)RangeProcedure durations Total procedure time, minutes42.3 ± 12.825-78 Fluoroscopy time, minutes18.5 ± 6.210-35Embolization materials Coil-only use48 (60.0)- Coil + plug combination28 (35.0)- Coil + sclerotherapy4 (5.0)- Mean coil number (left ovarian vein)4.8 ± 1.62-9 Mean coil number (right ovarian vein)4.2 ± 1.52-8 Plug use (Amplatzer)28 (35.0)-Embolized veins Bilateral ovarian vein68 (85.0)- Only left ovarian vein10 (12.5)- Only right ovarian vein2 (2.5)- Internal iliac vein tributaries (additional)47 (58.75)-Technical success Complete embolization success80 (100)- Complete occlusion on control venography80 (100)- No residual reflux80 (100)- Technical details and success rates of endovenous ovarian vein embolization (OVE) procedures At the 6-month follow-up, significant improvements occurred in all outcome measures (all P < .001): the VAS decreased by 3.12 ± 2.51 points (Cohen's d = 1.68), FSFI increased by 7.28 ± 4.86 points (d = 1.21), ASEX decreased by 9.45 ± 6.34 points (d = 1.47), Hamilton Depression decreased by 6.8 ± 3.6 points, Hamilton Anxiety scale decreased by 8.1 ± 4.2 points, and quality of life increased by 28.42 ± 16.15 points (d = 2.24). Response rates were 88.7% for pain and quality of life, 86.2% for sexual function (FSFI), and 87.5% for the ASEX. Pelvic pain decreased in 93.7% of patients, dyspareunia improved in 91.2%, and vaginismus resolved in 95.2%. These improvements were sustained at the 6-month follow-up with minimal regression of symptoms, indicating durable treatment benefit. Fig 2 demonstrates multidimensional treatment response by comparing baseline and 6-month follow-up scores for pain (VAS), sexual function (FSFI), sexual experience (ASEX), depression (Hamilton Depression scale), anxiety (Hamilton Anxiety scale), and quality of life. Fig 3 summarizes symptom-specific response and resolution rates, including pelvic pain, dyspareunia, vaginismus, overall pain response, sexual function response, and quality-of-life response. Fig 4 presents the Pearson correlation matrix among multidimensional outcome measures, demonstrating the inter-relationship between pain, psychosexual function, psychiatric symptoms, and quality of life. Supplementary Tables I through XII contain detailed demographic characteristics, SVP classification subgroups, anatomical findings, scale score changes by time point, and subgroup analyses for readers interested in comprehensive data.Fig 2Multidimensional treatment response: Endovenous ovarian vein embolization (OVE) for pelvic congestion syndrome (PCS). ASEX, Arizona Sexual Experiences Scale; HAM-A, Hamilton Anxiety scales, HAM-D, Hamilton Depression scales; FSFI, Female Sexual Function Index; QoL, quality of life; VAS, visual analog scale.Fig 3Treatment response rates: Symptom resolution after endovenous ovarian vein embolization (OVE). FSFI, Female Sexual Function Index; VAS, visual analog scale.Fig 4Correlation matrix: Multidimensional outcomes. ASEX, Arizona Sexual Experiences Scale; HAM-A, Hamilton Anxiety scales, HAM-D, Hamilton Depression scales; FSFI, Female Sexual Function Index; QoL, quality of life; VAS, visual analog scale. Multidimensional treatment response: Endovenous ovarian vein embolization (OVE) for pelvic congestion syndrome (PCS). ASEX, Arizona Sexual Experiences Scale; HAM-A, Hamilton Anxiety scales, HAM-D, Hamilton Depression scales; FSFI, Female Sexual Function Index; QoL, quality of life; VAS, visual analog scale. Treatment response rates: Symptom resolution after endovenous ovarian vein embolization (OVE). FSFI, Female Sexual Function Index; VAS, visual analog scale. Correlation matrix: Multidimensional outcomes. ASEX, Arizona Sexual Experiences Scale; HAM-A, Hamilton Anxiety scales, HAM-D, Hamilton Depression scales; FSFI, Female Sexual Function Index; QoL, quality of life; VAS, visual analog scale. Minor complications occurred in 6.25% of patients (local phlebitis in two cases, groin hematoma in two cases, and intraoperative minimal coil migration in one case). No major complications were observed. All minor complications were successfully managed with conservative measures or snare retrieval, and no patient required reintervention. Multivariate analysis identified three independent predictors of treatment response: dysmenorrhea (OR, 3.24; 95% CI, 1.52-6.91), high parity (≥4 births; OR, 2.87; 95% CI, 1.31-6.29), and prolonged symptom duration (≥2 years; OR, 2.15; 95% CI, 1.04-4.44).10 Patients with dysmenorrhea were 3.24 times more likely to achieve clinical response, suggesting that menstrual cycle-related symptoms may indicate greater vascular pathology amenable to embolization. Higher parity and prolonged symptom duration were also associated with an increased odds of response, supporting their consideration during patient counseling and selection. Fig 5 demonstrates the three independent predictors of treatment response identified by multivariate logistic regression analysis.Fig 5Predictors of treatment response: Multivariate logistic regression analysis. OR, Odds ratio. Predictors of treatment response: Multivariate logistic regression analysis. OR, Odds ratio. Discussion This prospective single-arm cohort study demonstrates that endovenous OVE produces significant, sustained improvements in pain, sexual function, psychiatric health, and quality of life in patients with PCS. However, the absence of a control group limits causal attribution, as improvements may partially reflect placebo effect, regression to the mean, or natural fluctuation in chronic pelvic pain.11 Therefore, these findings should be interpreted as demonstrating clinical benefit rather than superiority over other therapies. The high response rates and large effect sizes are notable, yet effect sizes from pre-post analyses without comparison groups may overestimate treatment effects. The magnitude of improvement across multiple outcome domains suggests a meaningful clinical benefit for patients with PCS. The identification of dysmenorrhea, high parity (≥4 births), and prolonged symptom duration (≥2 years) as predictors of response provides valuable clinical guidance for patient selection. Patients with these characteristics may be preferentially selected for endovenous treatment. The multidisciplinary approach integrating vascular surgery and psychiatry addresses the complex psychosocial burden of PCS. Psychiatric collaboration during initial assessment and ongoing support throughout treatment enabled comprehensive evaluation of psychiatric symptoms and sexual function.12 This study was conducted at a single center with a relatively homogeneous patient population; cultural and socioeconomic factors may influence the reporting of sexual function and psychiatric symptoms, limiting generalizability.13 Study limitations This study has several limitations that should be considered when interpreting the findings. First, the single-arm design without a control or sham treatment group limits causal inference, and the observed improvements may be influenced by placebo effect, regression to the mean, or natural fluctuation of chronic pelvic pain. Second, the single-center setting and relatively homogeneous patient population may restrict external validity. Third, the 6-month follow-up period is short for assessing long-term recurrence, durability of venous occlusion, and late complications. Fourth, psychosexual outcomes may be affected by confounding factors such as relationship dynamics, cultural attitudes toward sexual reporting, psychiatric comorbidity, and concurrent nonprocedural interventions. Finally, selection bias may have occurred because only patients with venographically confirmed PCS and complete follow-up data were included. Conclusions Endovenous OVE is a safe and effective minimally invasive treatment for PCS, providing multidimensional improvement and significantly enhancing pain relief, sexual function, psychiatric health, and quality of life. The favorable safety profile (6.25% minor complications) and high response rates support its use as first-line therapy. A multidisciplinary management approach involving vascular surgery and psychiatry collaboration is essential for optimal patient outcomes. Although the single-arm design limits causal attribution, the high response rates and favorable safety profile substantiate significant clinical benefit. Future comparative studies with control groups are needed to definitively establish efficacy and identify optimal patient selection criteria. Data Availability The data used in the study cannot be shared openly due to patient confidentiality and KVKK (Turkish Personal Data Protection Law) compliance requirements. Requests for data access may be directed to the corresponding author. Author Contributions Conception and design: TOB, HAU, HU Analysis and interpretation: TOB, SP, HU Data collection: TOB, FC, AC, SP, HU Writing the article: TOB, SP Critical revision of the article: TOB, FC, AC, SP, HAU, HU Final approval of the article: TOB, FC, AC, SP, HAU, HU Statistical analysis: TOB Obtained funding: Not applicable Overall responsibility: Not applicable Funding None. Disclosures None.